The Next Healthcare Arbitrage: PE And VC Bet On Compounding Pharmacies
Flush with funding and surging demand, compounding pharmacies are attracting capital from private equity firms, venture capital firms, and hospitals, reshaping the pharmaceutical power dynamic from the bottom up.
This is Part 2 of a two-part series on compounding pharmacies. In A Dose Of Disruption: How Compounding Pharmacies Are Challenging Big Pharma On GLP-1 Drugs And Drug Patents, we explored how compounders are rewriting the rules on GLP-1s and drug patents. Now, we turn to the capital behind the curtain—how private equity, venture capital, and hospital systems are fueling the rise of an alternate pharmaceutical infrastructure.
I. From Niche to Infrastructure: The Rise of Compounding
Big Pharma has long operated like a legal cartel—protected by evergreening patents, backroom pay-for-delay deals, and control over formularies that dictate which drugs insurers and hospitals will cover. It reinforces this dominance through aggressive lobbying, public relations campaigns, and billions spent on direct-to-consumer and physician marketing. But cracks are forming. Amid persistent drug shortages and growing demand for personalization, a quieter revolution is taking hold.
The Evolution of Compounding Pharmacies
Compounding pharmacies, once the backrooms of mom-and-pop drugstores, are evolving into a multibillion-dollar infrastructure play. Investors are waking up to the fact that the next big pharmaceutical disruption may not come from the lab—it might come from the compounding bench.
Market forecasts peg the U.S. compounding pharmacy sector at $6.31 billion in 2024, projected to reach $10.76 billion by 2033, growing at a CAGR of 6.1%. This expansion is driven by drug shortages, telehealth, chronic conditions, rising consumer demand for personalization, and increased provider interest in patient-centered care.
Therapeutic Focus: Hormone therapy, dermatology, chronic pain, sexual health, pet meds, longevity and personalized medicineRegulatory Categories: FDA 503A (traditional compounders), 503B (outsourcing facilities)Key Players: Empower Pharmacy, QuVa Pharma, Leiters, VLS Pharmacy, PCCARisks: Sterility concerns, FDA scrutiny, lack of drug approval for compounded versions, state–federal oversight inconsistenciesSources: BioSpace, Nova One Advisor, FDA, company websites
Compounding pharmacies address deep structural inefficiencies in the pharmaceutical system. They offer a flexible response to drug shortages and supply fragility, serve patients needing personalized or niche formulations, and operate outside the opaque pricing mechanisms dominated by just a few major pharmaceutical companies. For patients, they represent a more accessible and responsive alternative—especially in the context of rising telehealth adoption.
What makes this model particularly attractive to investors is its strong financial profile. First, compounded medications often treat chronic conditions like hormone therapy or dermatological issues, creating reliable subscription-based revenue. Second, many compounders handle their own fulfillment, bypassing pharmacy benefit managers (PBMs) and wholesalers—leading to significantly higher margins. Third, customer acquisition costs (CAC) are often low, thanks to prescriber-driven referrals and integrated telehealth platforms. Finally, regulatory arbitrage allows compounders to legally operate under FDA 503A and 503B exemptions—producing medications without full FDA approval, provided they meet specific patient or clinical use requirements.
The legacy image of the compounder—splitting pills behind the counter—no longer applies. Today's leaders are deeply embedded into healthcare infrastructure. These platforms don't just fill scripts—they control the entire patient experience, from diagnosis to doorstep.
Vertical Integrators:
Platform Partners (Non-Owners):
The competitive pressure isn't just coming from startups. Giants like Amazon have entered the pharmacy space with mail-order prescriptions, fulfillment infrastructure, and its $1B+ acquisition of PillPack—reshaping consumer expectations around convenience, speed, and price transparency. While Amazon doesn't operate in compounding, its presence adds urgency for verticalized platforms to differentiate through personalization and specialty formulations.
Personalized medicine is no longer limited to tailoring doses—it's becoming a cornerstone of the rapidly growing longevity economy. As wealthy consumers, biohackers, and digital health platforms chase enhanced immunity, energy optimization, and age reversal, compounding pharmacies are increasingly part of the protocol.
Biohackers like Bryan Johnson—whose multimillion-dollar quest to reverse aging includes aggressive biomonitoring, nutrient tracking, and intravenous therapies—have helped bring visibility to personalized protocols. IV drips for immune support, NAD+, hydration, and energy are now offered not just in wellness clinics, but in luxury medspas, concierge practices (for optimizing IVF results and longevity), and hotel suites across major cities. Many of these formulations originate from compounding pharmacies, which supply customized injectables, infusions, or troches based on client goals and lab results.
In the oncology space, personalized adjunct therapies—like low-dose naltrexone, topical pain relievers, and customized hormone or sleep aids—are often compounded to support patients alongside conventional treatment. These niche interventions highlight compounding's ability to fill therapeutic gaps that mass-manufactured drugs can't reach.
The demand is scaling fast—fueled by longevity clinics, telehealth labs, personalized diagnostic startups, and medspas. Investors are beginning to recognize that compounding pharmacies are not just reactive stopgaps. They're becoming critical infrastructure for proactive, precision-driven medicine that caters to a future of biologically tuned care.
Compounding pharmacies operate under FDA's 503A and 503B guidance, outside the NDA pathway. This enables them to: 1) bypass patents, 2) serve during shortages, and 3) personalize formulations.
In 2023–24, compounded GLP-1s like semaglutide exploded in popularity due to shortages and affordability. Hims, Ro, and others jumped in, as detailed in The GLP-1 Revolution—Everyone (And Their Moms) Are On GLP-1s. TikTok amplified the demand.
Then came the blowback:
Yet demand persisted. Empower Pharmacy, a scaled 503B facility, continues to fill tens of thousands of GLP-1 scripts monthly.
The sector is under growing scrutiny:
Still, Empower has retained the support of respected clinicians.
'If I need something, I would get it from Empower,' said Dr. Larry Lipshultz, a urologist at Baylor College of Medicine.
'There's no question that you're dealing with a first-class operation.'
He estimates Empower's alternatives are up to 80% cheaper than branded drugs—a crucial differentiator for out-of-pocket payers.
Big Pharma has also seen quality missteps. Most recently, Sandoz recalled a lot of cefazolin due to mispackaging, underscoring that safety lapses are industry-wide.
Private Equity:
Venture Capital:
Hospital Systems:
This cross-capital convergence shows compounding isn't a fringe workaround—it's becoming fundamental infrastructure.
As detailed in A Dose of Disruption: How Compounding Pharmacies Are Challenging Big Pharma On GLP-1 Drugs And Drug Patents, compounded medicine is redefining price, personalization, and access.
If courts crack down on patent evergreening and capitalized compounders keep scaling, a decentralized, faster, cheaper alternative to Big Pharma could emerge.
As compounders scale across B2B (hospitals) and B2C (telehealth), regulatory compliance becomes make-or-break.
503B compounders must demonstrate proactive compliance and high-quality controls. QuVa (Bain) and Leiters (hospital-backed) are well-positioned. Empower remains under scrutiny, even as it scales.
Any major incident could reshape public trust—and investor interest.
If Big Pharma is the last legal drug cartel, then compounding pharmacies are its insurgents—and PE and VC are backing them for a market coup. In this battle over price, trust, and access, the rebels aren't just disrupting—they're rebuilding.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
36 minutes ago
- Yahoo
India slams Trump's threat of tariffs over Russian oil purchases
India fired back at the United States after President Trump pledged to increase tariffs on New Delhi over the country's purchase of Russian oil. In a statement Monday, India's Ministry of External Affairs (MEA) said the purchase of Russian oil is a 'necessity' to 'ensure predictable and affordable energy costs' and was once 'encouraged' by the U.S. 'for strengthening global energy markets stability.' The MEA spokesperson further suggested the West is being hypocritical, pointing to trade that the European Union and the United States has continued to do since the war between Russia and Ukraine began. 'In this background, the targeting of India is unjustified and unreasonable,' the spokesperson said in the statement. 'Like any major economy, India will take all necessary measures to safeguard its national interests and economic security,' it added. The pushback from India comes after Trump said on Monday he would raise tariffs on India for buying and selling oil from Moscow, arguing the country doesn't care about the Ukrainian casualties suffered at the hands of 'the Russian War Machine.' Trump did not specify the new tariff rate but said it would increase from the 25 percent tariff the U.S. president said he would impose last month. 'India is not only buying massive amounts of Russian Oil, they are then, for much of the Oil purchased, selling it on the Open Market for big profits,' Trump said on Truth Social. 'They don't care how many people in Ukraine are being killed by the Russian War Machine. Because of this, I will be substantially raising the Tariff paid by India to the USA.' Trump previously vowed to hit India with a penalty for buying military equipment and energy from Russia amid the war in Ukraine. China is also a major importer of Russian oil, but has not faced the same threats from Trump. Trump in recent weeks has grown increasingly frustrated with Russian President Vladimir Putin and shortened the timeline for him to agree to a ceasefire in Ukraine to Aug. 8, at which point Trump has said he will impose 'secondary tariffs' of up to 100 percent on Russia's trading partners in a bid to isolate Moscow economically. India said it would continue buying oil from Moscow on Saturday. The Indian foreign ministry called the relationship with Russia 'steady and time-tested' and said its stance on security energy is guided by the availability of oil in the markets. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed. Solve the daily Crossword
Motor Trend
2 hours ago
- Motor Trend
Porsche Said To Be Readying All-New, Gas-Powered Compact SUV
Even as the present U.S. administration is busy rolling back emissions regulations, much of the rest of the world continues to tighten theirs, forcing automakers including Porsche into making tough decisions about whether or not to replace aging gas-powered models with EVs. At present, Porsche is taking a "let's do both" approach with its Macan compact SUV that currently exists as both an ICE and purely electric-powered vehicle. But it's gradually phasing out the gas-fed Macan, which is already gone in Europe and will soon be here in America as well. So, it's EVs only now for Porsche from here on out? Not so fast, as it appears that a new compact crossover Porsche is developing to join the Macan in its lineup will be a gas-fed model, possibly a hybrid of some form. Porsche is developing a new gas-powered compact SUV to join its lineup by 2028, potentially replacing the current gas-only Macan. This model may include a hybrid version and will be distinct from the Macan EV, reflecting Porsche's adaptive strategy to market demands. This summary was generated by AI using content from this MotorTrend article. Read Next According to a recent Car and Driver report, Oliver Blume, CEO of Porsche, stated on an earnings call that there's a gas-powered crossover on track to join the Porsche SUV lineup as soon as 2028, that may come with a new name. While the size will probably be very close to that of the current Macan, this new SUV will be distinct from the Macan EV that will continue with that nameplate. We contacted Porsche to see what we could get confirmed, but it's not terribly much. 'Once the combustion-engine models of the same name have been phased out, the Macan will be sold exclusively as an all-electric model, worldwide,' a Porsche spokesperson told us via email. 'At the same time, Porsche is continuously monitoring market development and customer demand. If necessary, the company looks ahead and adapts its product strategy.' Part of that evolving product strategy for the new compact SUV may be to add a hybrid version of the model to supplement any pure, gas-powered engine option. Porsche also confirmed that this smaller crossover will be entirely unique from the Macan EV but will have similar sporting characteristics that make it a Porsche and that it 'would benefit from synergies.' While Porsche wouldn't confirm the 2028 timeframe that Car and Driver stated from Blume, the spokesperson said it's expected to be launched 'towards the end of the decade.'
Yahoo
2 hours ago
- Yahoo
Trump wants more American pick-ups in Tokyo and London. That may be a hard sell
By David Dolan, Maki Shiraki and Marie Mannes TOKYO/STOCKHOLM, August 7 (Reuters) -Donald Trump is right that Japan and Europe buy few American-made cars - but it has little to do with trade barriers. From Tokyo to London, many consumers see Detroit's offerings as simply too big and too gas-guzzling. Switch Auto Insurance and Save Today! The Insurance Savings You Expect Affordable Auto Insurance, Customized for You Great Rates and Award-Winning Service That view has made Chevrolets and Cadillacs a hard sell, and a rare sight, in cities full of slimmer cars from the Toyota Corolla to Honda Civic, Volkswagen Golf and Renault Clio. Trump often complains about what he sees as a refusal to accept U.S. cars while the Japanese and Europeans sell millions of automobiles a year into the United States. In recent trade deals, both markets agreed to drop or ease safety tests on American vehicle imports. Europe will lower levies on U.S. cars. But it may take more than a change of rules and lower tariffs to convince Japanese and European consumers, who contend with narrow roads and painfully tight parking, to buy big American-made Ford F-150 trucks and Cadillac Escalade SUVs. "American cars are designed for wide roads and freeway driving, so handling them on narrow Japanese streets can be tricky. It takes a bit of technique," said Yumihito Yasue, president of Johnan Jeep Petit in Tokyo, which imports and services vintage cars from the United States. His customers tend to be enthusiasts in their 50s and 60s who grew up seeing American cars on TV and in movies. On a recent weekday, he was servicing two Chevrolets, a lustrous brown 1971 Nova and a low-slung 1986 El Camino, both with their steering wheels on the left. In Japan, steering is on the right. Yasue inherited his love of American cars from his father, who started the business four decades ago and would travel to California to scout for cars. Yasue took over after his father died nine years ago, and sells about 20 vehicles a year. "What makes American cars special is the design. Compared to Japanese or German cars, the body shape is more beautiful. Especially the lines, like the rear lines and the fenders," he said. Some 3.7 million new cars were sold in Japan last year, with a third of those mini or "kei" cars - tiny, fuel efficient vehicles not produced by American automakers. Overall, foreign cars accounted for 6% of new car sales, data from the Japanese Automobile Manufacturers Association showed. Of those, around 570 Chevys, 450 Cadillacs and 120 Dodges were sold, data from the Japan Automobile Importers Association showed. Ford pulled out of Japan almost a decade ago. Tesla makes cars sleeker than some of Detroit's and is becoming more popular. The data does not give a breakdown for the EV maker. 'WE DON'T BUY FORD F-150S' In Europe, smaller locally-made U.S. cars have done well: models like the best-selling Ford Puma and the older Fiesta. But over the past two decades, Ford and General Motors have pivoted towards larger pickups and SUVs, vehicles less suited to Europe's narrow streets and compact-car culture. Ford, a big player in Europe from the early 1900s, has seen sales in the region fall sharply, from 1.26 million vehicles in 2005 to just 426,000 in 2024, according to data from the European Automobile Manufacturers' Association (ACEA). Its market share dropped from 8.3% to 3.3%. "We don't buy Ford F-150s, that's not what our roads are scaled for, it's not what our customers want," Andy Palmer, former CEO of Aston Martin, told Reuters. GM exited Europe in 2017, selling Opel after pulling back Chevrolet, but returned with its Cadillac Lyriq last year. It sold a mere 1,514 of the U.S.-made SUV, according to auto data firm Jato. A GM spokesperson said Cadillac was growing its all-electric lineup in Europe, and the vehicles had been well-received in the markets where they were launched. A Ford spokesperson said the firm exported "passion products" to Europe like the Bronco and Mustang, alongside locally-made models tailored for the market. Clive Sutton, a British car dealer in London who sells luxury American models, said his buyers were drawn to the rarity of vehicles like the giant Cadillac Escalade. But he admitted it was a challenge. "There are people that want that car because of its exclusivity and its perceived status," Sutton said. "But it's not the most easy car to find a parking space for, certainly in central London." COMPETITIVE MARKET Trump has also put pressure on South Korea to open its market to American cars and said duty-free access was part of the trade deal the two countries agreed last week. There, imported vehicles account for less than one-fifth of the car market and U.S. models for only 16% of the imported car segment, which is dominated by German rivals, according to data from the Korea Automobile Importers & Distributors Association. German manufacturers have also carved out a strong presence in Japan's luxury market. Mercedes-Benz sold more than 53,000 vehicles last year, making it the most popular foreign brand, followed by BMW at more than 35,000. Japanese automakers say Europeans have been successful because they committed the time and resources to the market. Detroit carmakers, meanwhile, are often associated with left-hand drive cars, which are more challenging to drive on the left-hand side of the road. But some U.S. manufacturers are changing. GM has offered the Corvette only in right-hand drive since the eighth generation version went on sale in 2021. That may be one reason why some 80% of buyers are new customers, a GM spokesperson said. The Corvette is the only model Chevy offers in Japan, and it has sold fewer than 1,000 of them a year for the last decade. GM this year announced plans for a line-up of right-hand-drive Cadillac EVs and deliveries of the Lyriq started in July. 'WOW, A FOREIGN CAR' Jeep, which sells right-hand drive models, has been the most popular American brand for more than a decade, the importer data showed. It sold just shy of 10,000 vehicles last year in Japan. Yukimi Nitta used to drive a "kei" car but she was drawn to the Jeep Wrangler's appearance, which she described as "friendly" and "outdoorsy". The 42-year-old hair salon owner is now on her second Jeep - a limited-edition beige model - and hopes to switch again to another limited-edition colour. Parking is tight but manageable, she said, and two of her friends have since bought Wranglers. "People often say, 'Wow, a foreign car!' But once you drive it, it feels totally normal. I wish more people would try it," she said. While the Wrangler does burn through fuel quickly, the resale value is good, making it possible to switch out colours, something owners do, Nitta said. A spokesperson for Jeep owner Stellantis said it actively promoted owner events. In July, it announced a collaboration with the "Jurassic World" movie series featuring a limited-edition pink Wrangler, the spokesperson said. Big American cars and trucks might find it hard to follow in Jeep's tracks. Daniel Cadwell, an American living in Tokyo, exports used Japanese camper vans and wagons to the United States. He said he was struck by the size of American cars whenever he went home. "They are just excessively big," said Cadwell, who runs Javan Imports in Portland with his U.S.-based business partner. "I think it is highly challenging for a car of that sort to be seen as attractive in Japan."
